Empasug 10mg

Description:

• Empasug 10mg contains empagliflozin 10 mg, a selective SGLT2 inhibitor used as a foundational therapy for T2DM. This once-daily oral tablet reduces blood glucose levels by increasing urinary glucose excretion. It has been shown to lower cardiovascular death and reduce hospitalizations in patients with established heart disease.
• As a leading diabetes medicine manufacturer, we ensure consistent quality standards and regulatory compliance across all batches.
• Recognized among top empagliflozin 10mg tablets exporters, this formulation meets global demand with precision and safety.

Key Features:

• Effective as monotherapy or in combination antihyperglycemic therapy
• Promotes glucose excretion, lowers HbA1c, and improves insulin sensitivity
• Delivers cardiovascular risk reduction in high-risk T2DM patients
• Supports renal protection in diabetic kidney disease
• Offers weight control benefits in overweight diabetic patients
• Trusted by leading diabetes drugs manufacturers for its proven therapeutic efficacy and tolerability
• Manufactured by a certified empagliflozin 10mg tablets manufacturer under stringent quality control processes

Usage Guidelines:

• Take once daily, preferably in the morning
• May be initiated in adults inadequately controlled on diet and exercise
• Renal function should be assessed prior to initiation

Safety Profile:

• Possible side effects: genital infections, polyuria, and dizziness
• Not indicated in type 1 diabetes or diabetic ketoacidosis
• Monitor for volume depletion, electrolyte imbalance, or hypotension

Uses / Indications: Improves blood sugar control, Reduces cardiovascular death and hospitalization, Slows kidney disease progression and reduces heart risks